Clinical trial NCT01358071: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer
Official title: NGR018: Randomized Phase II Study of NGR-hTNF Plus an Anthracycline Versus an Anthracycline Alone in Platinum-resistant Ovarian Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Ovarian Cancer
Keywords: NGR-hTNF
Pegylated liposomal doxorubicin
Doxorubicin
Platinum-resistant
Progression or recurrence Ovarian Cancer
Ovarian Cancer
Advanced or metastatic
Lead sponsor: AGC Biologics S.p.A.
Sponsor class: INDUSTRY
First posted: 2011-05-23
Enrollment: 119
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this randomized phase II trial is to compare progression-free survival (PFS) in patients randomized to NGR-hTNF plus an anthracycline versus patients randomized to an anthracycline alone

Detailed description: Considering the safety/toxicity profile of NGR-hTNF characterized by mild-to-moderate constitutional symptoms, the reversibility of these adverse events generally occurring only during the infusion time; the absence of overlapping toxicities with chemotherapeutic agents; the safety and preliminary antitumor activity observed in previous trial with doxorubicin; and the objective response rate (RR) registered in a phase II trial in previously treated ovarian cancer patients seems justified to evaluate in a randomized phase II trial the efficacy of NGR-hTNF against a doxorubicin-based option in advanced ovarian cancer patients progressing or recurrent after a standard platinum/taxane-based chemotherapy.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Histologically-proven ovarian cancer, fallopian tube and primary peritoneal cancer in advanced or metastatic stage
* Patients previously treated with a maximum of two platinum-based regimen plus paclitaxel and with documented progressive disease on treatment (refractory patient population) or within 6 months from last chemotherapy cycle (resistant patient population)
* ECOG Performance status 0 - 2
* Life expectancy of 12 weeks or more
* Normal cardiac function
* Adequate baseline bone marrow, hepatic and renal function defined as follows:

  1. Neutrophils ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L; hemoglobin ≥ 9 g/dL
  2. Bilirubin ≤ 1.5 x ULN
  3. AST and/or ALT ≤ 2.5 x ULN in absence of liver metastasis or ≤ 5 x ULN in presence of liver metastasis
  4. Serum creatinine \< 1.5 x ULN
* At least one (not previously irradiated) target lesion or non-measurable disease only, according to RECIST criteria
* Patients may have had prior therapy providing the following conditions are met:

  * Surgery and radiation therapy: wash-out period of 14 days
  * Systemic anti-tumor therapy: wash-out period of 21 days
* Patients must give written informed consent to participate in the study

Exclusion Criteria:

* Patients must not receive any other investigational agents while on study
* More than two previous chemotherapy lines and previous treatment with anthracycline
* Patients with myocardial infarction within the last six months, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication
* Prolonged QTc interval (congenital or acquired) \> 450 ms
* History or evidence upon physical examination of CNS disease unless adequately treated
* Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol
* Known hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients
* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol
* Pregnancy or lactation.

Primary outcomes:
measure: Progression-Free Survival (PFS)
timeFrame: from the date of randomization, every 6 and 8 weeks based on type of chemotherapy during treatment and every 12 weeks during the follow-up until PD or death
Secondary outcomes:
measure: Overall survival (OS)
timeFrame: from the date of randomization, every 6 and 8 weeks based on type of chemotherapy during treatment and every 12 weeks during follow-up until death
measure: Response Rate (RR)
timeFrame: from the date of randomization, every 6 and 8 weeks based on type of chemotherapy during treatment and every 12 weeks during the follow-up until PD or death
measure: Disease Control Rate (DCR)
timeFrame: from the date of randomization, every 6 and 8 weeks based on type of chemotherapy during treatment and every 12 weeks during the follow-up until PD or death
measure: Duration of Disease Control
timeFrame: from the date of randomization, every 6 and 8 weeks based on type of chemotherapy during treatment and every 12 weeks during the follow-up until PD or death
measure: Safety and Toxicity according to NCI-CTCAE criteria (version 4.03)
timeFrame: from the start of treatment until 28 days after last treatment
Other outcomes:
Locations:
city: Milan
country: Italy
facility: Ospedale San Raffaele
city: Milan
country: Italy
facility: Fondazione IRCCS Istituto Nazionale dei Tumori
city: Milan
country: Italy
facility: Istituto Europeo di Oncologia
city: Naples
country: Italy
facility: Istituto Nazionale Tumori IRCCS Fondazione "Giovanni Pascale"
city: Perugia
country: Italy
facility: Ospedale S. Maria della Misericordia
city: Rome
country: Italy
facility: Policlinico Universitario "Agostino Gemelli"
city: Glasgow
country: United Kingdom
facility: Beatson Oncology Centre, Gartnavel Hospital
state: Scotland
city: Bebington
country: United Kingdom
facility: Clatterbridge Centre for Oncology
state: Wirral
Study officials:
affiliation: AGC Biologics S.p.A.
name: Antonio Lambiase, MD
role: STUDY_DIRECTOR
References: